Team:HKUST-Hong Kong/Design Overview

From 2012.igem.org

(Difference between revisions)
 
(11 intermediate revisions not shown)
Line 363: Line 363:
<p>
<p>
<br>
<br>
-
In this project, we would to introduce our genetically engineered Bacillus subtilis, B. hercules, as an anti-colon-tumor agent to provide direct tumoricidal effect during cancer therapy. It is applied as oral medicine which retains viability through digestive tract and executes anti-tumor activity when and only when it is binding to colon cancer cell. Three modules are designed and assembly together to achieve our final goal. <br><br>
+
In this project, we would like to introduce our genetically engineered <i>Bacillus subtilis</i>, B. hercules, as an anti-tumor agent to suppress colon tumor growth during cancer therapy. It is to be applied as an oral medicine which retains viability through the digestive tract and executes anti-tumor activity when - and only when - it is binding to colon cancer cells. Three modules are designed and assembled to achieve our final goal. <br><br>
<b><font size="3">1. Target Binding</b></font><br><br>
<b><font size="3">1. Target Binding</b></font><br><br>
-
Driven by <i>Pveg </i>constitutive promoter, RPMrel, the colon-tumor specific peptide is designed to be displayed on the cell wall of<i> B. subtilis </i>under the facilitation of LytC cell wall displaying system. With this peptide displaying, <i>B. subtilis </i>is taken orally by patient. It is expected to reach colon without retaining or colonizing in gastrointestinal tract. However, once it reaches colon, it will be held up around colon tumor cells and colonize around them, waiting for signal to produce anti-tumor molecule to the local environment. For detailed description, please refer to module: <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Target_binding">Target Binding Module</a><br><br>
+
Driven by <i>Pveg </i>constitutive promoter, RPMrel, the colon-tumor binding peptide is designed to be displayed on the cell wall of<i> B. subtilis </i>under the facilitation of LytC cell wall display system. With this peptide displayed, <i>B. subtilis </i>is taken orally by patient. The engineered bacterial cells are expected to reach colon without colonizing the upper gastrointestinal tract. However, once it reaches the colon, it will be held up around colon tumor cells and colonize, waiting for the signal to produce anti-tumor molecule and secrete it to the local environment. For detailed description, please refer to module: <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Target_binding">Target Binding Module</a><br><br>
-
<b><font size="3">2. Anti-tumor molecule synthesis:</b></font><br><br>
+
<b><font size="3">2. Anti-tumor molecule Secretion:</b></font><br><br>
-
BMP2 (Bone morphogenetic protein 2) has been reported to be a colon tumor suppressor. It arrests cells in G1 phase and triggers the apoptosis of colon cancer cell. To enable the production and secretion of BMP2, type I signaling peptide from secretion protein in <i>B. subtilis </i>is fused to the N terminus of mature BMP2 originated from mouse genome. The expression of this fusion protein is under xylose inducible promoter originated from <i>Bacillus megaterium</i>. Since no xylose is present in colon, xylose coated in enteric capsules can be taken orally to induce the production of BMP2 in colon when B. subtilis has successfully localized around colon tumor. For detailed description, please refer to module: <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Anti_tumor">Anti-tumor Molecule Synthesis </a><br><br>
+
BMP2 (Bone morphogenetic protein 2) has been reported to be a colon tumor suppressor. It arrests cells in G1 phase and triggers the apoptosis of cancerous colon epithelial cells. To enable the production and secretion of BMP2, type I signaling peptide from secretion protein in <i>B. subtilis </i>is fused to the N- terminus of mature BMP2 originated from mouse genome. The expression of this fusion protein is controlled under xylose inducible promoter originating from <i>Bacillus megaterium</i>. Since no xylose is normally present in colon, xylose coated in enteric capsules can be taken orally to induce the production of BMP2 in colon when the <i>B. subtilis</i> vector has successfully localized around colon tumor. For detailed description, please refer to module: <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Anti_tumor">Anti-tumor Molecule Secretion </a><br><br>
-
<b><font size="3">3. Regulation and control system: </b></font><br><br>
+
<b><font size="3">3. Regulation and control System: </b></font><br><br>
-
Two regulatory systems are designed in order to controlling the timing and dosage of anti-tumor cytokine produced in colon. Xylose inducible promoter is used in our project to determine the time of BMP2 produced. When and only when <i>B. subtilis</i> has bound to colon tumor cell, will BMP2 production be initiated. <br><br>
+
Two regulatory systems are designed in order to control the timing and dosage of anti- tumor cytokine production in the colon. Xylose inducible promoter is used in our project to determine the timing of BMP2 production. Only when the genetically modified <i>B. subtilis</i> has bound to colon tumor cells will BMP2 production be initiated. <br><br>
-
While the locally concentrated BMP2 is expected to suppress colon tumor grow and trigger the apoptosis of tumor, the adverse effect from over-dose BMP2 is also designed to be prevented from a toxin-antitoxin system. While antitoxin YdcD is produced under the control of a low efficiency promoter <i>Ptms,</i> YdcE (toxin) is designed to be expressed simultaneously with BMP2 under the driving of xylose inducible promoter. When BMP2 is intensively produced under the inducing from xylose, the expression of YdcE (toxin) will overwhelm the protection threshold from antitoxin YdcD. The overexpression of toxin with BMP2 production will therefore cause the growth inhibition of <i>B. subtilis</i> and stop any protein synthesis under this stress condition. For detailed description, please refer to module: <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Regulation_and_control">Regulation and Controlling System.</a> <br><br>
+
While the locally concentrated BMP2 is expected to suppress colon tumor growth and induce tumor cells to enter apoptosis, the possible adverse effects from BMP2 overdose should also be taken into consideration. In our design, this is made preventable by introducing a toxin-antitoxin system. When the antitoxin YdcD is produced under the control of a low efficiency promoter <i>Ptms,</i> YdcE (EndoA, toxin) is designed to be expressed simultaneously with BMP2, driven by the xylose inducible promoter. When BMP2 is intensively produced under xylose induction, the expression of YdcE (EndoA, toxin) will overwhelm the protection limit of antitoxin YdcD (EndoAI). The overexpression of toxin together with BMP2 production will therefore inhibit the growth of <i>B. subtilis</i>, and result in the termination of protein synthesis activity. For detailed description, please refer to module: <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Regulation_and_control">Regulation and Controlling System.</a> <br><br>
-
<p align="center"> <img src="https://static.igem.org/mediawiki/2012/0/07/Whole_project.JPG" width="70%" /></p>
+
<p align="center"> <img src="https://static.igem.org/mediawiki/2012/0/07/Whole_project.JPG" width="80%" /></p>
Line 384: Line 384:
#paragraph1{
#paragraph1{
-
background-color:#CCFB5D;
+
background-color:#EDFFFF;
width:955px;
width:955px;
height:auto;
height:auto;
Line 398: Line 398:
</style>
</style>
 +
 +
<div id="Sitemap">
 +
<div id="Sitemap_Home" align="center">
 +
<p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong"><b>Home</b></a></p>
 +
</div>
 +
<div class="Sitemap_Content">
 +
<li><p><b>Team</b><p><ol>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Introduction">Introduction</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Supervisor">Supervisor</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Instructor">Instructor</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Members">Members</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Advisors">Advisors</a></p></li>
 +
</ol>
 +
</div>
 +
<div class="Sitemap_Content">
 +
<li><p><b>Project</b></p><ol>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Project_Abstraction">Abstract</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Background_and_Motive">Motive</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Design_Overview">Design - Overview</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Design_Module">Design - Module</a></p></li>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Target_binding">Target Binding Module</a></p>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Anti_tumor">Anti-tumor Molecule Secretion Module</a></p>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Module/Regulation_and_control">Regulation and Control Module</a></p>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Design_Chassis">Design - Chassis</a></p></li></ol>
 +
</div>
 +
<div class="Sitemap_Content">
 +
<li><p><b>Wet Lab</b></p><ol>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Parts_and_Device">Parts and Devices</a></p></li>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Parts_and_Device">Overview</a></p>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Construction">Construction</a></p>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Assembly">Assembly</a></p>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Notebook">Notebook</a></p></li>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Notebook/Logbook">Logbook</a></p>
 +
<p>-- <a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Notebook/Protocol">Protocol</a></p>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Characterization">Characterization</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Achievement">Achievement</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Future_Work">Future Work</a></p></li></ol>
 +
</div>
 +
<div class="Sitemap_Content">
 +
<li><p><b>Human Practice</b></p><ol>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Overview">Overview</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Interview">Interview</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Presentation">Presentation</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Calendar">Calendar</a></p></li></ol>
 +
</div>
 +
<div class="Sitemap_Content">
 +
<li><p><b>Extras</b></p><ol>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Medal_Requirements">Medal Requirements</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Safety">Safety</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Attribution">Attribution</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Acknowledgement">Acknowledgement</a></p></li>
 +
<li><p><a href="https://2012.igem.org/Team:HKUST-Hong_Kong/Glossary">Glossary</a></p></li></ol>
 +
</div>
 +
</div>
 +
<style type="text/css">
 +
#Sitemap{
 +
background-image:url('https://static.igem.org/mediawiki/2012/c/c0/HKUST_Campus.jpg');
 +
background-color:#ffffff;
 +
width:955px;
 +
height:auto;
 +
float:left;
 +
margin-top:5px;
 +
margin-bottom:5px;
 +
padding-bottom:5px;
 +
padding-top:5px;
 +
padding-left:4px;
 +
border:3px solid #000000;
 +
border-radius:10px;
 +
-moz-border-radius:10px;
 +
}
 +
.Sitemap_Content{
 +
background-color:#ffffff;
 +
opacity:0.8;
 +
width:173px;
 +
height:auto;
 +
float:left;
 +
margin:1px;
 +
padding-bottom:5px;
 +
padding-left:5px;
 +
border:3px solid #000000;
 +
border-radius:10px;
 +
-moz-border-radius:10px;
 +
}
 +
#Sitemap_Home{
 +
background-color:#ffffff;
 +
opacity:0.8;
 +
width:940px;
 +
height:auto;
 +
float:left;
 +
margin:1px;
 +
padding-bottom:5px;
 +
padding-left:5px;
 +
border:3px solid #000000;
 +
border-radius:10px;
 +
-moz-border-radius:10px;
 +
}
 +
</style>
 +
</body>
</body>
</html>
</html>

Latest revision as of 03:31, 27 September 2012

Team:HKUST-Hong Kong - 2012.igem.org

Design Overview


In this project, we would like to introduce our genetically engineered Bacillus subtilis, B. hercules, as an anti-tumor agent to suppress colon tumor growth during cancer therapy. It is to be applied as an oral medicine which retains viability through the digestive tract and executes anti-tumor activity when - and only when - it is binding to colon cancer cells. Three modules are designed and assembled to achieve our final goal.

1. Target Binding

Driven by Pveg constitutive promoter, RPMrel, the colon-tumor binding peptide is designed to be displayed on the cell wall of B. subtilis under the facilitation of LytC cell wall display system. With this peptide displayed, B. subtilis is taken orally by patient. The engineered bacterial cells are expected to reach colon without colonizing the upper gastrointestinal tract. However, once it reaches the colon, it will be held up around colon tumor cells and colonize, waiting for the signal to produce anti-tumor molecule and secrete it to the local environment. For detailed description, please refer to module: Target Binding Module

2. Anti-tumor molecule Secretion:

BMP2 (Bone morphogenetic protein 2) has been reported to be a colon tumor suppressor. It arrests cells in G1 phase and triggers the apoptosis of cancerous colon epithelial cells. To enable the production and secretion of BMP2, type I signaling peptide from secretion protein in B. subtilis is fused to the N- terminus of mature BMP2 originated from mouse genome. The expression of this fusion protein is controlled under xylose inducible promoter originating from Bacillus megaterium. Since no xylose is normally present in colon, xylose coated in enteric capsules can be taken orally to induce the production of BMP2 in colon when the B. subtilis vector has successfully localized around colon tumor. For detailed description, please refer to module: Anti-tumor Molecule Secretion

3. Regulation and control System:

Two regulatory systems are designed in order to control the timing and dosage of anti- tumor cytokine production in the colon. Xylose inducible promoter is used in our project to determine the timing of BMP2 production. Only when the genetically modified B. subtilis has bound to colon tumor cells will BMP2 production be initiated.

While the locally concentrated BMP2 is expected to suppress colon tumor growth and induce tumor cells to enter apoptosis, the possible adverse effects from BMP2 overdose should also be taken into consideration. In our design, this is made preventable by introducing a toxin-antitoxin system. When the antitoxin YdcD is produced under the control of a low efficiency promoter Ptms, YdcE (EndoA, toxin) is designed to be expressed simultaneously with BMP2, driven by the xylose inducible promoter. When BMP2 is intensively produced under xylose induction, the expression of YdcE (EndoA, toxin) will overwhelm the protection limit of antitoxin YdcD (EndoAI). The overexpression of toxin together with BMP2 production will therefore inhibit the growth of B. subtilis, and result in the termination of protein synthesis activity. For detailed description, please refer to module: Regulation and Controlling System.